Latest News about IONS
Recent news which mentions IONS
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
December 20, 2024
Tickers
IONS
From Benzinga
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
December 20, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 12, 2024
From Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
October 31, 2024
From Benzinga
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 10, 2024
From Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
September 10, 2024
From Benzinga
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
August 26, 2024
Tickers
IONS
From Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
From Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
From Benzinga
From Benzinga
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31, 2024
From Benzinga
From Benzinga
From InvestorPlace
Tickers
IONS
From InvestorPlace
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
March 13, 2024
From Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
From Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
February 01, 2024
Tickers
IONS
From Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
From Benzinga
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
January 22, 2024
From Benzinga
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
January 18, 2024
Tickers
IONS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.